My Lords, I join other noble Lords in thanking my noble friend Lord Patel for his leadership of the Science and Technology Committee, for the thoughtful way in which he led this inquiry into science research funding in our universities and for how he introduced this debate. In so doing, I declare my own interest as professor of surgery at University College London, chairman of UCLPartners, and an active biomedical researcher.
We have heard during the debate that the future funding of the research base in our universities is important not only to the universities themselves, but to our country more generally. It is our ambition that we become an economy driven by technology and innovation, and to be able to deliver that we have to have the appropriate science base in our universities. We have seen in recent months, with the Covid-19 pandemic, the importance of the science base to protect our population and drive forward innovation. Life science, as it has been described in this debate and in previous debates in your Lordships’ House, is, after the financial services industry, the second most important part of our economy. It employs directly some 250,000 people, with a further 250,000 jobs dependent on life sciences in our country.
The United Kingdom has been at the forefront of research developments in the Covid-19 pandemic, demonstrating the importance of the availability of an effective and mature research base in our universities to address critical questions at a moment’s notice. This report, as we have heard, was published over a year ago, before the Covid-19 pandemic and its implications for our universities, and, of course, before the withdrawal agreement from the European Union had been concluded —and, indeed, before the current trade negotiations have run their course. The impact of our departure from the European Union and the broader impact on our economy that it will have on our research funding remain most pertinent.
I will focus on two issues. With Brexit, as we have heard during this debate, it is essential that Her Majesty’s Government commit to three principal areas. Yes, of course, one is funding to ensure that the shortfall that will arise as a result of our no longer being able to participate directly in European funding schemes is met by Her Majesty’s Government. However, that funding shortfall must also facilitate collaborative research within the European Union—that is, our own university collaborative participation—as well as collaboration with research networks elsewhere in the world. Of course, we must also do everything to ensure that mobility of researchers is maintained. In this regard, the points made by the noble Lord, Lord Willetts, are critical, on ensuring that the visa system facilitates the ability of not only researchers to come to our country, but their families too.
Secondly, on public funding for research, we have heard about the importance of ensuring that QR funding, that second important element of the dual support
mechanism, is maintained at levels that guarantee an inflationary increase. We need also to ensure that the shortfall in funding provided by charities to support research in our universities, particularly biomedical research, is addressed. Charities are responsible for some 15% of research funding. As we have heard in this debate, a 1% reduction in support for universities is expected this year.
5.35 pm